Pieris AG has achieved the fourth milestone payment for its lead Anticalin® program with Daiichi Sankyo Company, Limited (hereinafter Daiichi Sankyo; headquartered in Chuo Ward, Tokyo, TSE 4568), triggering an undisclosed payment, the company announced today. This milestone marks in total the sixth milestone achieved for the parties’ two R&D collaborative projects. Specifically, the milestone was the decision by Daiichi Sankyo to initiate a GLP toxicity study in non-human primates. In 2013, Pieris transferred the program to Daiichi Sankyo, which is responsible for further development of the program.
{iframe}http://www.streetinsider.com/Press+Releases/Pieris+Achieves+GLP+Tox+Milestone+Payment+in+Daiichi+Sankyo+Collaboration+to+Develop+Anticalin(R) Therapeutics/10075721.html{/iframe}